SONOMA PHARMACEUTICALS INC (SNOA)
US83558L2043 - Common Stock
Overall SNOA gets a fundamental rating of 2 out of 10. We evaluated SNOA against 198 industry peers in the Pharmaceuticals industry. SNOA may be in some trouble as it scores bad on both profitability and health. SNOA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SNOA had negative earnings in the past year.
SNOA had a negative operating cash flow in the past year.
In the past 5 years SNOA always reported negative net income.
In the past 5 years SNOA always reported negative operating cash flow.
1.2 Ratios
SNOA has a Return On Assets (-34.72%) which is comparable to the rest of the industry.
With a Return On Equity value of -75.85%, SNOA perfoms like the industry average, outperforming 47.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.72% | ||
| ROE | -75.85% | ||
| ROIC | N/A |
ROA(3y)-28.36%
ROA(5y)-37.9%
ROE(3y)-65.58%
ROE(5y)-73.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SNOA (39.18%) is comparable to the rest of the industry.
SNOA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.8%
GM growth 5Y-4.15%
2. Health
2.1 Basic Checks
SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNOA has been increased compared to 1 year ago.
Compared to 5 years ago, SNOA has more shares outstanding
SNOA has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -17.65, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
SNOA has a Altman-Z score of -17.65. This is amonst the worse of the industry: SNOA underperforms 84.10% of its industry peers.
SNOA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
SNOA has a Debt to Equity ratio (0.01) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.65 |
ROIC/WACCN/A
WACC8.08%
2.3 Liquidity
A Current Ratio of 4.07 indicates that SNOA has no problem at all paying its short term obligations.
SNOA has a Current ratio of 4.07. This is comparable to the rest of the industry: SNOA outperforms 57.44% of its industry peers.
A Quick Ratio of 3.11 indicates that SNOA has no problem at all paying its short term obligations.
SNOA has a Quick ratio (3.11) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.07 | ||
| Quick Ratio | 3.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.74% over the past year.
The Revenue has decreased by -1.93% in the past year.
SNOA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.45% yearly.
EPS 1Y (TTM)55.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.2%
Revenue 1Y (TTM)-1.93%
Revenue growth 3Y-9.55%
Revenue growth 5Y-4.45%
Revenue growth Q2Q6.73%
3.2 Future
SNOA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.13% yearly.
Based on estimates for the next years, SNOA will show a quite strong growth in Revenue. The Revenue will grow by 19.32% on average per year.
EPS Next Y40.28%
EPS Next 2Y30.31%
EPS Next 3Y24.13%
EPS Next 5YN/A
Revenue Next Year12.61%
Revenue Next 2Y17.33%
Revenue Next 3Y19.32%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNOA. In the last year negative earnings were reported.
Also next year SNOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNOA's earnings are expected to grow with 24.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.31%
EPS Next 3Y24.13%
5. Dividend
5.1 Amount
No dividends for SNOA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SONOMA PHARMACEUTICALS INC
NASDAQ:SNOA (5/6/2024, 10:13:22 AM)
0.16
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.50M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.72% | ||
| ROE | -75.85% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.18% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.07 | ||
| Quick Ratio | 3.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)55.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y40.28%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.93%
Revenue growth 3Y-9.55%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y